Kata®

The digital revolution in the treatment of respiratory diseases

With the new health app Kata® combining artificial intelligence and computer animation, the German company VisionHealth achieves a revolutionary improvement in the inhalation treatment of pneumological diseases.

Did you know?

People

More than 600 million people worldwide suffer from chronic respiratory infections such as asthma and COPD.[9] [10] [11] [12]

People

Each year, over 3.5 million people die as a result of these chronic respiratory infections.[9] [10] [11] [12]

of patients

never receive training for their inhaler. [13] [14] [15]

Correct inhalation is the key to success in treatment.

Inhalation is much more complex than swallowing a tablet!

Patients

Up to 90% of patients do not perform their prescribed inhalation therapy correctly. [1] [2] [3]

Inhalers

In Germany alone, more than 160 different combination preparations with MDI and DPI inhalers are approved.

In addition to poor adherence to therapy, uncontrolled respiratory disease is often related to improper inhalation technique. Inhaled therapies can stabilize diseases and alleviate or suppress symptoms, however, according to physicians, the drugs administered in this way are often ineffective. This is because the inhalation process, which seems so simple, is inherently fragile. The ever-changing device-drug combinations – generics as well as orginators – pose challenges for both patients and medical staff.

Operating a complex mix of inhaler devices, different nominal doses, and drug combinations is a difficulty for those affected. As a result of lack of explanation and practice, many patients make mistakes in operation. However, correct inhalation is very important in many cases. Studies impressively prove that an improved handling of inhalation systems enables a significantly better therapy success. [6],[7],[8]

An enormous cost factor

The potential for a mobile and digital healthcare solution is highly attractive due to the high number of patients, the enormous savings potential using the intelligently linked technologies, and upcoming changes in healthcare policy.

approx.

Critical inhalation errors increase average annual treatment costs by €497-535 per patient. [16] [17]

Dollars

To treat chronic lung disease, it took $64.8 billion in 2015 for inhaled medications alone. And the trend is heading upwards.

Dollars

More than $160 billion in additional direct and indirect costs worldwide each year. [5]

VisionHealth provides digital therapy support for patients with chronic respiratory diseases between doctor visits.

We launched Kata® for this purpose: The digital solution using our algorithm to promote improved adherence management. Inhale – without the need for a local medical expert on site or remote diagnosis.

The combination of artificial intelligence, machine learning, computer animation and augmented reality achieves a never before seen worldwide revolutionary improvement in inhalation management of pneumological diseases.

Our innovation offers benefits for patients, health insurers, physicians, the state and, last but not least, for young technology companies.

Kata® puts an end to treatment errors!

Using the patient’s own smartphone, Kata® automatically trains the patient to inhale correctly – without the need for a local medical expert on site or remote diagnosis.

Kata®: Easy handling, versatile application

Digital support

Asthma, COPD and other chronic respiratory diseases requiring inhalation therapy.

Unique methodology

Real-time training for patients during daily use.

Enabling technology

Transversal application adapted to all inhaler types. Does not require expensive and complicated hardware component adjustments.

Continuous data

Daily symptom and therapy records enable clinicians to make well-informed treatment decisions.

Condition reports

Reports on disease progression and adherence through Kata®. Empower patients to monitor their medication and detect subtle changes.

Big Data

Collection of anonymized data through Kata®. Supports optimization of the particular drug and methodology.

These experts are already convinced!